X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Featured

US President Looks To Double The Drugs For Price Negotiation

Content Team by Content Team
18th March 2023
in Featured, Insights, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

President Joe Biden is looking to double the number of medicines that Medicare can help negotiate rates for and thereby enable the government to start those discussions more quickly, as per a budget proposal for 2024 that was released recently.

Joe Biden’s plan would build on the Inflation Reduction Act that was passed in 2022, which gave Medicare the power to broker prices when it came to some top-selling drugs. The law would help Medicare negotiate prices on 10 drugs in 2026 and up to almost 140 drugs by 2033.

As per Bloomberg Law, which cited data that it received from the Centers for Medicare and Medicaid Services, the budget from Biden will double these totals, with 20 drugs available for negotiations initially and 300 by 2033. There has been no comment from the CMS in this regard.

The budget also calls for making these drugs eligible for price negotiations much sooner than in the case of the IRA. Apparently, the White House is looking for the ability to begin those discussions five years after the drugs reach the market.

It is well to be noted that small molecule drugs are as of now exempt for nine years, while large molecule or biologic drugs come with a longer exclusivity period of 13 years.

According to Xavier Bacerra, US Department of Health and Human Services Secretary, are there reasons why American citizens should pay two- or three-times more for prescription medicines as compared to someone in, say, France, Australia, Canada, or even Mexico? They are entitled to the best price for all the prescription medicines, he added. Notably, the White House annual budget proposal happens to be a wish list document that is typically meant to stake out positions when it comes to the upcoming legislative session as well as future elections. As per RBC Capital Markets Brian Abrahams, who happens to be an analyst, the bill in this form or any other form similar to this is likely going to be a non-starter given that there is going to be a significant amount of opposition from the Republicans.

However, he still expressed his concerns that drug pricing is continued as a negotiation tool and that the current debate may not get off the table as many had otherwise expected following the IRA’s passage in 2022.

Joe Biden’s plan counters the proposal from Republicans so as to cut Medicare spending when it comes to healthcare services to avert the depletion of the Hospital Insurance Trust Fund, which was an outcome the government had projected may take place in 2028.

Previous Post

Monash University In Australia Leads $15M Mitochondrial Clinical Trial Drive

Next Post

Cell And Gene Therapy Boost With Novel UK Biotech Centres

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Role of CDMOs In Technology Transfer From Molecule To Market
Insights

Role of CDMOs In Technology Transfer From Molecule To Market

19th June 2025
CDMOs Driving Agile Production Within Intricate Therapies
Insights

CDMOs Driving Agile Production Within Intricate Therapies

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
Next Post

Cell And Gene Therapy Boost With Novel UK Biotech Centres

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In